Human fibrocytes are mesenchymal progenitors that exhibit mixed morphological and molecular characteristics of hematopoietic stem cells, monocytes and fibroblasts. They likely represent the obligate intermediate stage of differentiation into mature mesenchymal cells of a bone marrow-derived precursor of the monocyte lineage under permissive conditions. On in vitro stimulation with pro-fibrotic cytokines and growth factors, human fibrocytes produce large quantities of extracellular matrix components and further differentiate into cells identical to the contractile myofibroblasts that emerge at the tissue sites during repair processes and in some fibrotic lesions. Studies in various animal models of wound healing or fibrotic diseases have confirmed the ability of fibrocytes to differentiate into mature mesenchymal cells in vivo and have suggested a causal link between fibrocyte accumulation and ongoing tissue fibrogenesis or vascular remodeling in response to tissue damage or hypoxia. Fibrocytes synthesizing new collagen or acquiring myofibroblast markers have been detected in human hypertrophic scars, in the skin of patients affected by nephrogenic systemic fibrosis, in human atherosclerotic lesions, and in pulmonary diseases characterized by repeated cycles of inflammation and repair, like asthma. The presence of fibrocyte-like cells has been reported in human chronic pancreatitis and chronic cystitis. Similar cells also populate the stroma surrounding human benign tumors. The available data indicate that human fibrocytes serve as a source of mature mesenchymal cells during reparative processes and in fibrotic disorders or stromal reactions predominantly associated with a persistent inflammatory infiltrate or with the selective recruitment of monocytes induced by ischemic changes and tumor development. A deeper understanding of the mechanisms involved in fibrocyte differentiation in these pathological conditions may lead to the development of novel therapies for preventing detrimental tissue or vascular remodeling and metastatic progression of invasive tumors.
The fibrocytes [1] [2] [3] [4] [5] are bone marrow-derived mesenchymal progenitors [6] [7] [8] [9] that coexpress hematopoietic stem cell antigens, markers of the monocyte lineage and fibroblast products. [1] [2] [3] [4] [5] [6] 10, 11 They constitutively produce extracellular matrix (ECM) components as well as ECM-modifying enzymes, [1] [2] [3] 5, 11 and can further differentiate into myofibroblasts both in vitro and in vivo under permissive micro-environmental conditions. 3, 5, 10, 11 There is increasing evidence that these cells contribute to the new population of fibroblasts and myofibroblasts that emerge at the tissue site during normal 1, 3, 6 or aberrant 12 wound healing, in ischemic or inflammatory fibrotic processes, 8, 9, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and as part of the stromal reaction to tumor development. 13, [24] [25] [26] [27] [28] [29] [30] [31] [32] This review will focus on the origin of human fibrocytes and their involvement in the pathogenesis of reactive and reparative fibroses in human diseases.
HEMATOPOIETIC ORIGIN AND MESENCHYMAL PROPERTIES OF HUMAN FIBROCYTES Origin and Phenotypic Characteristics
The term fibrocyte was first used in 1994 to define a subpopulation of leukocytes that accumulate at sites of tissue injury and show fibroblast properties. 1 In the initial report, fibrocytes were found to express the hematopoietic stem cell/ progenitor marker CD34, the leukocyte common antigen CD45 (a pan-hematopoietic marker) and several markers of the monocyte lineage in conjunction with vimentin and collagens. 1 The phenotypic characteristics of these cells were further evaluated in subsequent studies 3, 5, [10] [11] [12] 23, [33] [34] [35] and the markers of human fibrocytes are shown in Table 1 .
Bucala and co-workers initially estimated that fibrocytes comprise 0.1-0.5% of the 'circulating' population of nonerythrocytic cells on the basis of the number of fibrocytes isolated from cultures of peripheral blood mononuclear cells, 1, 2 but additional experiments from the same group 3 and from other investigators 4, 5, 10, 23 revealed that human fibrocytes may not be present in the peripheral blood as such and may originate from a circulating precursor. The most recent data suggest that fibrocytes mature from a subpopulation of CD14
þ peripheral blood mononuclear cells [3] [4] [5] 10, 23 that express the receptors for the Fc portion of immunoglobulin G (IgG) FcgRI (CD64) and FcgRII (CD32) and do not express FcgRIII (CD16) 5, 9, 10 (Table 1) . Therefore, circulating fibrocytes precursors may be present in a small fraction of the CD14 þ CD16 À subset of human mononuclear cells that bear the CC chemokine receptor (CCR)2 on their surface and are analogous to the murine Ly-6C high CCR2
þ mononuclear cells, expressing low levels of the CX 3 C chemokine receptor 1. [38] [39] [40] This subset constitutes an immature subpopulation of cells that are normally present in the circulation and have been termed 'inflammatory' monocytes. 38 In absence of inflammation, they likely serve to replenish the tissue-resident macrophage and dendritic cell populations after an initial differentiation into different subtypes of monocytes before they enter the tissues. 38 During inflammatory processes, they are released in high number from the bone marrow into the peripheral blood and directly migrate to inflamed sites, predominantly through a CCR2-mediated signaling pathway. [38] [39] [40] Once migrated to the tissue sites, most of these precursors are thought to differentiate 
The symbols represent no expression (À), marginal or no expression (+/À) and increasing level of expression (+, ++), and have been arbitrarily assigned to each marker on the basis of published data. [1] [2] [3] [4] [5] 10, 11, 17, 23, 36, 37 a Although some studies [2] [3] [4] [5] 11, 17 have confirmed the initial report 1 that human mature fibrocytes do not express CD14, subsequent serial phenotypic analyses of these cells in culture have revealed that fibrocytes downregulate to various extent, but may still retain CD14 expression as they mature from CD14 + monocytes. 10, 23 Actually, the apparent lose of CD14 expression in previous studies [2] [3] [4] [5] 11, 17 might be explained with the use of anti-CD14 antibodies to deplete 'contaminating' cells before harvesting fibrocytes from cultures of peripheral blood mononuclear cells. Not expressed by 'inflammatory' monocytes. 38, 39 c von Willebrand factor (endothelial cell marker). (Table 1) . The maturation process is also associated with the early upregulation of hematopoietic stem cell/progenitor markers that are no longer expressed by mature monocytes, 42 such as CD34 23 and CD105 5 ( Table 1 ). The hypothesis that fibrocytes, like some dendritic cells subsets, derive from precursors of the monocyte lineage is supported by the evidence that these cells express the major histocompatibility complex class I and class II and the costimulatory molecules CD80 and CD86 (Table 1) , 1, 5, 10, 34, 35 exhibit antigen-presenting activity 34 and activate both CD4 þ and CD8 þ T lymphocytes. 34, 35 However, they lack specific markers of monocyte-derived dendritic cells such as CD1a, CD10 and CD83 (Table 1) .
The combination of collagen production and expression of CD45 or one of the hematopoietic (CD34) or myeloid antigens (CD11b, CD13) is considered as a sufficient criterion to discriminate fibrocytes from leukocytes, dendritic cells, endothelial cells and tissue-resident fibroblasts in vitro and in vivo. 1, 3, 5, [10] [11] [12] 23 Fibrocytes can be distinguished from circulating or tissue-resident mesenchymal stem cells/multipotent mesenchymal stromal cells, because the latter cells express fibroblast products but are CD90-positive and do not express CD34 or CD45 or the monocyte markers. 45, 46 Human mesenchymal stem cells residing in the bone marrow can express CD34, CD45 and CXCR4 to various extents, but remain negative for monocyte markers. 47 
Development and Mesenchymal Properties
Although initial studies demonstrated the development of fibrocytes from peripheral blood mononuclear cells after 10-14 days of culture in media containing high concentrations of serum, [1] [2] [3] [4] subsequent investigations revealed that human CD14 þ mononuclear cells differentiate into fibrocytes within 3 days in serum-free media. 5, 10, 48 Moreover, whereas the fibrocytes that emerge in serum-free cultures of peripheral blood mononuclear cells already express high levels of prolyl 4-hydroxylase, the enzyme required for the synthesis of new collagen, 10 fibrocytes developed in serumsupplemented media show low prolyl 4-hydroxylase activity in comparison with mature fibroblasts. 36 However, fibrocytes are immature mesenchymal cells that do not produce large amounts of collagenous proteins or other ECM components until they differentiate into mature fibroblasts and myofibroblasts, 11 but are an important source of ECM-degrading enzymes, primarily matrix metalloproteinase-9 (MMP-9). 37 Several factors affect the development of fibrocytes from the CD14 þ precursor and the differentiation of fibrocytes into mature mesenchymal cells. 3, 5, [10] [11] [12] 23, 48 Direct contact between peripheral blood CD14 þ mononuclear cells and T lymphocytes in co-cultures and stimulation of peripheral blood CD14 þ mononuclear cells with transforming growth factor-b 1 (TGF-b 1 ) (either added as a recombinant protein or derived from CD14 À mononuclear cells) increase the yield of fibrocytes. 3, 12 Platelet-derived growth factor (PDGF), 23 interleukin (IL)-4 and IL-13 48 also promote the differentiation of CD14 þ mononuclear cells into fibrocytes. By contrast, stimulation of CD64 or CD32 by aggregated IgG or serum amyloid P (SAP) inhibits the development of fibrocytes from CD14 þ mononuclear cells. 10 SAP is a constitutive serum protein in most species and it has been identified as the active factor in serum that inhibits fibrocyte differentiation from the CD14 þ mononuclear cells in serum-supplemented cultures. 5, 10 This molecule, which belongs to the pentraxin family of autacoids, is produced by the liver and its levels increase at tissue sites only during the early phase of inflammatory reactions associated with the extravasation of serum proteins, being rapidly cleared or inactivated at a later stage. 5, 10, 48 Pro-inflammatory cytokines like interferon-g (IFNg) and IL-12 inhibit the differentiation of fibrocytes from CD14 þ mononuclear cells in serum-free media. 48 IL-1b does not affect the maturation of fibrocytes from the monocyte precursors, 48 but induces proliferation of mature fibrocytes and reduces the release of collagens from these cells. 2 Once fibrocytes have completed their maturation from CD14 þ mononuclear cells, further differentiation into cells ultrastructurally and phenotypically similar to mature fibroblasts and myofibroblasts is promoted by stimulation with TGF-b 1 3,11 and endothelin-1 (ET-1). 11 The resulting cell population produces much more collagens and fibronectin than fibrocytes, 3, 11 express the myofibroblast marker asmooth muscle actin (a-SMA), 3, 11, 19 and downregulate the expression of CD34 and CD45. 11, 19 Spontaneous differentiation of fibrocytes into a-SMA þ cells also occurs, albeit to a much lesser extent, in unstimulated cultures, 3, 5, 10, 11 particularly in serum-free media 10, 11 and may be due to the autocrine production of TGF-b 1 .
2 It is still unclear as to whether the myofibroblasts that mature from fibrocytes retain their ability to present antigens and activate certain T cell subsets. The recent observation that fibrocytes can transform into adipocytes when cultured under adipogenic conditions 33 
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Laboratory Investigation | Volume failed to obtain similar results in sex-mismatched bone marrow chimera mice, probably because total body irradiation with only 800 rads was not sufficient to ablate the bone marrow cell population in the female recipients before transplantation of the bone marrow from male donors.
6,18
Mechanisms by which fibrocytes populate peripheral organs Tracking experiments in murine models of wound healing 3 and chronic allergic asthma 11 have demonstrated that intravenously injected fibrocytes rapidly migrate to wounded or chronically inflamed sites and localize to areas of ongoing ECM deposition. 3, 11 However, data from three independent animal studies 9, 20, 23 suggest that this may not be the mechanisms by which fibrocytes populate peripheral organs, because the in vivo differentiation of fibrocytes from the circulating precursors may mainly occurs at the tissue sites and not in the peripheral blood. In the first study, 9 fibrotic cardiomyopathy with global ventricular dysfunction was induced in mice by multiple daily episodes of brief coronary artery occlusion. The fibrotic process was associated with a marked and prolonged induction of the production of CCR2 ligands in the cardiac tissue, recruitment of monocytes from the peripheral blood and subsequent accumulation of CD45 þ CD34 þ fibrocytes that expressed a canonical cardiac fibroblast marker and acquired in part the myofibroblast marker a-SMA. Daily treatment of mice with the inhibitor of fibrocyte differentiation SAP, while the animals were subjected to multiple daily episodes of brief coronary occlusion, inhibited the emergence of fibrocytes at the tissue site and markedly reduced the accumulation of myofibroblasts without affecting the nature and magnitude of the inflammatory response or the production of chemokines. The most likely explanation of these results is that the persistently high levels of active SAP interfered with the development of fibrocytes from the monocyte precursors taken up during the inflammatory response in the same manner as it occurs in vitro, when peripheral blood mononuclear cells are cultured in presence of serum. 5, 10 The second study 20 used neonatal animal models of hypoxia-induced pulmonary vascular remodeling to evaluate the possible role of fibrocytes in the pathogenesis of chronic pulmonary hypertension. In experiments where circulating monocytes/macrophages of chronically hypoxic rats were selectively labeled in vivo, the labeled cells were subsequently identified in the remodeled adventitial layer of the pulmonary arteries. Many of these cells, expressing CD45 and the monocyte markers CD14 and CD11b, progressively acquired the ability to synthesize new collagen while retaining expression of CD45 and CD11b. A substantial proportion of the cells expressing CD45 and monocyte markers also showed a-SMA immunoreactivity in vivo. These observations suggest that fibrocytes matured in the adventitial layer from the monocyte precursors taken up from the circulation and started to differentiate into myofibroblasts. The hypothesis that fibrocytes mature from the circulating precursor at the tissue site is also supported by the results of the third study by Varcoe et al, 23 who traced the path of the circulating cells that contributes to vascular remodeling in an ovine model of carotid artery intimal hyperplasia induced by vascular graft implantation. A subpopulation of the labeled circulating leukocytes that infiltrated the intima in vivo progressively acquired the fibrocyte phenotype (CD45 þ CD34 þ vimentin þ ) and showed a-SMA immunoreactivity during the remodeling process.
Interestingly, Moore et al 18 observed the emergence of CD45 þ CD13 þ fibrocytes, expressing collagen I gene and protein, in 10/14-day serum-free cultures of minced lung explants or bronchoalveolar lavage cells from mice with pulmonary inflammation and interstitial fibrosis induced by the intratracheal instillation of a toxicant, fluorescein isothiocyanate (FITC). Whether the lung explants or the bronchoalveolar lavage cell population contained fibrocytes or other cells of the monocyte lineage before being placed in culture is unknown. Much less fibrocytes emerged in cultures of minced lung tissue from mice lacking CCR2, which also showed a significant reduction in the fibrotic changes induced by FITC exposure. Transplantation of bone marrow cells from CCR2 þ / þ into lethally irradiated CCR2 À/À mice restored the ability to grow fibrocytes from minced explants of the injured lung and susceptibility to FITC-induced pulmonary fibrosis. The CD45 þ CD34 low collagen I þ cells emerging in cultures of minced lung tissue initially showed CCR2 expression, but this receptor was lost when fibrocytes were allowed to mature further in vitro for additional 7 days. These observations, 18 and further data from the same group, 21 suggest that the CCR2 ligands may play a pivotal role in the accumulation of fibrocytes during a fibrotic process triggered by a toxicant-induced inflammatory reaction in the lungs. The findings may be relevant to human fibrotic diseases, because the recruitment of human fibrocyte precursors (CD14 þ CD16 À mononuclear cells) into inflamed tissues, like the recruitment of the murine counterpart of inflammatory monocytes, is critically dependent on CCR2. 39, 40 Other studies have demonstrated an important role of the ligand of CXCR4, CXC chemokine ligand 12 (CXCL12), 17 and of one of the ligands of CCR7, CC chemokine ligand 21
www.laboratoryinvestigation.org | Laboratory Investigation | Volume 87 September 2007(CCL21), 19, 22 in the accumulation of fibrocytes in animal models of injury-induced pulmonary 17, 19 and renal fibrosis. 22 Because both human fibrocytes 3, 5 and the CD14 þ CD16
À subset of mononuclear cells 38 from which they appear to originate in vitro express CXCR4 and CCR7, these ligands may be involved in the accumulation of fibrocytes in some human fibrotic diseases.
Phenotypic changes associated with the differentiation of fibrocytes into myofibroblasts in vivo Two studies from our laboratory have provided key information on the ability of fibrocytes to differentiate into mature mesenchymal cells in vivo and on the phenotypic changes associated with the differentiation process. 6, 11 In an animal model of wound healing, 6 numerous CD45 þ CD13 þ collagen I þ fibrocytes of bone marrow origin could be isolated from digested fragments of wounded tissue between 4 and 7 days post-wounding, when inflammatory cells of the monocyte lineage are particularly abundant in the granulation tissue. 49 Collagen I expression was confirmed by demonstrating transcription from the pro-collagen I gene in the isolated cells. Whereas only a few fibrocytes showed a-SMA immunoreactivity at day 4 post-wounding, about 59% of these cells, on the average, were found to express the myofibroblast marker at day 7 post-wounding. The expression of a-SMA was confirmed at the gene level. The differentiation of fibrocytes into myofibroblast-like cells occurred in concomitance with increased production of TGF-b 1 in the wounded tissue and was associated with a progressive downregulation of the expression of CD34 and CD45, with only 21% of the a-SMA þ fibrocytes staining positively for CD34 at day 7. Similar CD45 þ CD34 À a-SMA þ cells of bone marrow origin where subsequently observed by another group at the same point in time post-wounding. 50 In the other study from our laboratory, 11 labeled CD34 þ collagen I þ a-SMA À fibrocytes were found to acquire the CD34 À collagen I þ a-SMA þ phenotype within 24 h from their localization in the subepithelial area of the airway wall of mice, where repeated cycles of allergen-induced inflammation caused excessive deposition of ECM molecules and thickening of the lamina reticularis. Taken together, the results of these studies directly demonstrate that fibrocytes can differentiate into mature myofibroblasts at the tissue sites during normal wound healing as well as in conditions where repeated inflammatory reactions prevent effective tissue repair and lead to fibrotic changes. They also indicate that, during this differentiation process, fibrocyte-derived myofibroblasts rapidly lose the surface markers that are currently used to distinguish them from fibroblast-derived myofibroblasts or other resident mesenchymal cells in vivo.
Causal link between fibrocyte accumulation and tissue fibrogenesis Evidence of a causal link between the accumulation of fibrocyte at injured sites and ongoing tissue fibrogenesis or vascular remodeling has been provided in various animal models of pulmonary, 11, 17, 19, 51 renal 22 and vascular diseases 20, 23 and in the model of ischemic cardiomyopathy mentioned above. 9 In these models, the fibrocytes appeared to contribute to the new population of collagen-producing cells 9, 11, 17, 19, 20, 22, 23 and/or a-SMA þ cells 9, 11, 19, 20, 23 that emerged at the injured tissue sites during the reactive/ reparative fibrotic process. Inhibition of fibrocyte accumulation by different means resulted in reduced collagen deposition 9, 17, 19, 20, 22, 23, 51 and reduced accumulation of myofibroblasts, 9, 17, 19, 20, 23 supporting the hypothesis that lesional fibroblasts and myofibroblasts mature at least in part from fibrocytes. However, fibrocytes themselves produce a number of cytokine and growth factors 2,37 that induce angiogenesis 37 or fibroblast hyperplasia 36 and promote the release of ECM molecules from resident tissue fibroblasts. 36 Therefore, the observed correlations between fibrocyte accumulation and ongoing tissue remodeling may also reflect the pro-fibrotic activity of these cells.
FIBROCYTE INVOLVEMENT IN HUMAN DISEASES Hypertrophic Scars and Keloids
Hypertrophic scars and keloids represent two different forms of aberrant wound healing and frequently develop as a consequence of extensive burn injury. [52] [53] [54] [55] Hypertrophic scars are predominantly characterized by the presence of narrow and widely spaced collagen fibrils that are arranged to form a nodular structure. 54, 55 In contrast, keloids contain thick collagen fibers composed of numerous fibrils packed together. 54, 55 Although an inflammatory infiltrate is present in both forms of excessive scarring, it is particularly evident in young lesions and in the hypertrophic form, and it is composed of T lymphocytes, monocytes and dendritic-like cells. 55 The nodules of hypertrophic scars show enhanced expression of TGF-b 1 mRNA, 56 the presence of cells actively synthesizing new collagens (pro-collagen I and III) 56 and numerous a-SMA myofibroblasts, which are also thought to cause the typical scar contractures. 54 Aiba and Tagami 57 detected dermal spindle-shaped cells coexpressing CD34 and proline-4-hydroxylase, the enzyme critically involved in collagen synthesis, in scars where the inflammation began to subside. By examining the immunohistochemical characteristic of dermal spindle-shaped cells at various stages of hypertrophic scar and keloid development, they observed that CD34 expression decreased over time, whereas the expression of proline-4-hydroxylase increased. In a more recent study, Yang et al 12 identified spindle-shaped cells coexpressing the leukocyte-specific protein-1 (LSP-1) and pro-collagen I in postburn hypertrophic scars. Similar cells also populated mature scars, but their density was a significantly lower than in hypertrophic scars. LSP-1 is one of the leukocyte markers expressed by fibrocytes (Table 1) and it is retained more stably than the transiently expressed CD34. Thus, taken together, the findings of these two studies indicate that fibrocytes contribute to the lesional fibroblast population present in 
Airway Remodeling in Asthma
Asthma is a common 58 and heterogeneous 59 inflammatory disorder of the airways, which usually shows a chronically relapsing course. Recurrent episodes of wheezing and shortness of breath manifest in concomitance with a worsening of the inflammatory infiltrate in the airways, and an abnormal broncho-constrictive response on exposure to a variety of environmental agents persists in the remission phases. In most forms of asthma, the bronchial mucosa of patients shows structural and functional abnormalities of the bronchial epithelium, an inflammatory infiltrate mainly composed of activated T lymphocytes, CD14 þ monocytes, eosinophils and mast cells, and remodeling of the airway tissue architecture. [60] [61] [62] [63] [64] [65] [66] Peculiar aspects of the remodeling process include angiogenesis, the accumulation of fibroblasts and myofibroblasts below the epithelial basement membrane, thickening of the lamina reticularis as a result of an excessive deposition of ECM molecules and bronchial smooth muscle cells hyperplasia. [65] [66] [67] [68] [69] [70] Repeated cycles of airway inflammation and repair with unsuccessful healing are thought to represent the driving force for most of these structural alterations, 66 as the bronchial mucosa of asthmatic patients resembles a wounded tissue where neither the inflammatory phase nor the reparative phase resolves completely. 19 The remodeling process ultimately leads to thickening of the airway wall and may cause the irreversible decline in lung function that can be observed in many patients with long-standing disease. [68] [69] [70] In the allergic form of asthma, every exposure to the allergens to which the patients are sensitized triggers an increased productions of chemokines and growth factors, including the CCR2 ligand monocyte chemoattractant protein-1 (MCP-1), ET-1 and TGF-b 1 , and further recruitment of CD14 þ monocytes, T helper (Th)2 lymphocytes and eosinophils into the bronchial mucosa. 62, 64, [71] [72] [73] [74] The inflammatory infiltrate is particularly abundant in the subepithelial area because epithelial cells are a major source of chemokines and growth factors. 19, 62, 72 It persists for days 73, 74 and is associated with the emergence of new myofibroblasts below the epithelial basement membrane within 24 h after allergen exposure. 75 One study from our group 11 demonstrated the appearance of fibrocytes, expressing CD34 in conjunction with pro-collagen I mRNA, in the airways of patients with allergic asthma between 4 and 24 h after the inhalation of the clinically relevant allergen. Within 24 h following allergen inhalation, a substantial proportion of the CD34 þ pro-collagen I mRNA þ cells also expressed a-SMA and localized to areas of new ECM deposition below the epithelial basement membrane. 11 As reviewed elsewhere, 72 the allergen-induced accumulation of fibrocytes in the bronchial mucosa of these patients is usually preceded by a worsening of the inflammatory infiltrate and is paralleled by an increased production of ET-1 from epithelial cells and endothelial cells and increased release of the biologically active form of TGF-b 1 from epithelial cells and eosinophils. The presence of activated T lymphocytes and the high levels of TGF-b 1 at the tissue site may promote the differentiation of fibrocytes from the CD14 þ monocytes recruited at an earlier stage, as a result of the increased production of MCP-1. Moreover, the peak increase in the release of ET-1 and TGFb 1 in the bronchial mucosa is observed at 24 h following allergen inhalation, and may favor further differentiation of fibrocytes into new myofibroblasts at this stage. 11, 72 Other cytokines produced by inflammatory cells 64, 66 may also contribute to promote the development of fibrocytes from their precursors (Th2 cell-derived IL-4 and IL-13) and induce fibrocyte proliferation (monocyte/macrophage-and dendritic cell-derived IL-1b).
Additional information on the role of fibrocytes in allergic asthma has been provided by other investigators 15 who detected CD34 þ CD45 þ a-SMA þ cells in bronchial biopsies from untreated patients with mild disease. These fibrocytes differentiating into myofibroblasts appeared in clusters close to the epithelial basement membrane and their density correlated with the thickness of the lamina reticularis. Moreover, similar cells spontaneously emerged in cultures of bronchoalveolar mononuclear cells from asthmatic patients, suggesting that there were fibrocyte precursors in the inflammatory infiltrate. The correlation between the number of a-SMA þ fibrocytes and the thickness of the lamina reticularis supports the hypothesis that fibrocyte-derived lesional myofibroblasts contribute to the deposition of new ECM molecules below the epithelium in asthma. In a more recent study, Kaur et al 16 demonstrated the expression of CCR7 in the myofibroblasts and other mesenchymal cells present in the bronchial mucosa of patients with asthma of various severities, confirming their possible origin from fibrocytes and their circulating precursors. These investigators also observed an increased production of the CCR7 ligand CCL19 by endothelial cells, mast cells and smooth muscle cells in asthmatic airways, suggesting that the CCL19/CCR7 axis may play an important role in the recruitment of mesenchymal precursors in asthma.
The accumulation of fibrocytes below the epithelial basement membrane in asthmatic airways may cause beneficial as well as detrimental effects. Although the excessive deposition of ECM molecules in the lamina reticularis by fibrocyte-derived myofibroblasts increases the thickness of the airway wall, both the fibrotic process and the contractile force generated by myofibroblasts may enhance the resistance to mechanical stress of a bronchial wall weakened by the inflammatory process, thereby preventing further damage, especially during broncho-constrictive episodes. On the other hand, fibrocyte produce basement membrane-degrading enzymes, such as MMP-9, and pro-angiogenic factors that facilitate normal wound healings, 37 but may have a deleterious effect in a wounded tissue where neither the inflammatory phase nor the reparative phase resolves completely. 19 Moreover, fibrocytes may be involved in the capture of the antigens that cross the epithelial barrier and present them to lamina propria CD4 þ and CD8 þ T lymphocytes. 34, 35 Therefore, these cells may work in concert with dendritic cells to amplify the allergic inflammatory reaction after every exposure to the relevant allergens. 64, 66 Interstitial Pulmonary Fibroses Idiopathic interstitial pneumonias are a heterogeneous group of rare chronic pulmonary diseases of unknown etiology that are characterized by varying degrees of inflammation and interstitial pulmonary fibrosis. 76 Idiopathic pulmonary fibrosis/usual interstitial pneumonia is the most common form. 76 This disease is unresponsive to currently available therapeutic options and frequently leads to death within 5 years from the time it has been diagnosed. [77] [78] [79] The chronic fibro-proliferative process is limited to the lung and is characterized by the presence of clusters of fibroblasts and myofibroblasts demarcated from surrounding cells (fibroblastic foci), which indicates active fibrogenesis. 80, 81 Myofibroblast are considered the dominant source of interstitial collagens and their persistence at the sites of active fibrogenesis is associated with poor prognosis, leading to progressive tissue remodeling, consequent loss of lung function and fatal outcome. 80, 81 Two groups 82, 83 have evaluated the possibility that fibrocytes are involved in the pathogenesis of idiopathic interstitial pneumonias. One study 82 was conducted in patients with idiopathic pulmonary fibrosis/usual interstitial pneumonia, nonspecific interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease and demonstrated the presence of cells coexpressing CCR7 and CD45 predominantly in the lung tissue specimens from patients with idiopathic pulmonary fibrosis/usual interstitial pneumonia. These cells did not express CD34 or a-SMA and they did not emerge specifically in areas of active collagen deposition. A diffuse pattern of CXCR4 expression was seen in all tissue specimens and most of the CXCR4 þ cells appeared to be infiltrating mononuclear cells. In the second study, 83 lung tissue bioptic specimens from patients with idiopathic pulmonary fibrosis/usual interstitial pneumonia and nonspecific interstitial pneumonia where compared with normal surgical tissue specimens. Increased expression of the CXCR4 ligand CXCL12 was observed in both fibrotic diseases. The investigators did not examine the lung tissue specimens for the presence of fibrocytes. However, they observed peripheral blood monocytosis in the patients with lung fibrotic diseases and could isolate higher number of CXCR4 þ
CD45
þ collagen I þ fibrocytes from the peripheral blood mononuclear cells of these patients than from the peripheral blood mononuclear cells of normal donors. Although the latter data suggest increased release of CXCR4 þ CD45 þ mesenchymal precursors from the bone marrow in patients with some forms of idiopathic interstitial pneumonias, there is at present no direct in vivo evidence of an increased accumulation of fibrocytes in the lungs of these patients.
In vitro experiments 84 have demonstrated the expression of functional CCR7 on fibroblasts isolated from the lungs of patients with idiopathic pulmonary fibrosis/usual interstitial pneumonia, but these cells do not seem to show the phenotypic characteristics of fibrocytes, being CD34 À CD45 À CD86 À cells. Moreover, normal fibroblasts also appear to contain CCR7 transcripts. 84 
Systemic Fibroses
Nephrogenic systemic fibrosis (also known as nephrogenic fibrosing dermopathy) is a disease that occurs almost exclusively in patients with renal dysfunction, particularly in those undergoing hemodialysis for end-stage renal disease. [85] [86] [87] The clinical course of the fibrotic disease is characterized by a symmetric and progressive hardening of the skin, which most commonly affects the extremities. 85, 87 Involvement of multiple organs, including heart, lungs, skeletal muscles and diaphragm, has been reported in many patients and the fibrotic process can ultimately lead to death. [85] [86] [87] The pathogenesis of this condition is unclear, but it has been recently associated with the use of gadolinium-containing contrast agents for magnetic resonance imaging. 86, 87 It has been proposed that the fibrotic lesions in the skin and in various organs may develop as a consequence of the deposition of the toxic gadolinium ions in the tissues of certain individuals with advanced renal disease, 86, 87 because they have metabolic acidosis or other conditions that favor the liberation of these ions. 86 The lesional skin and affected organs show a fibroproliferative process and a dense infiltrate, mainly composed of CD68 þ monocytes and abundant spindle-shaped cells that are immersed in a network of elastic fibers and collagen. [88] [89] [90] [91] The accumulation of CD68 þ monocytes at the tissue sites is a constant finding in early disease. 88, 90 Interstitial and vascular calcium deposits have been described in several affected tissues and may represent deposits of gadolinium with calcium phosphates 87 A pronounced increase in the thickness of the adventitial layer of small-and medium-size arterioles in the lungs and perivascular fibrosis in the small coronary arterioles in the heart have also been reported 91 and may result from gadolinium-induced endothelial damage, as suggested by animal studies. 92 The expression of CD34 and/ or CD45 on lesional spindle cells has been detected in various studies, 14, 88, 89, 91 one of which has unequivocally demonstrated that these cells are actually fibrocytes by double staining for CD45 and pro-collagen I. 14 In the involved tissues, such cells appear at an early stage of the fibrotic process 91 and localize to areas of active fibrogenesis. 14, 89, 91 Because high levels of TGF-b 1 mRNA have been observed in the lesional skin and affected muscles, 90 this growth factor may play a major role in the local differentiation of fibrocytes from the precursors of the monocyte lineage.
It has been proposed that fibrocytes may also been involved in the pathogenesis of systemic sclerosis. 93 This connective tissue disease of unknown etiology is characterized by autoantibody production, microvascular stenosis and excessive deposition of collagen in the skin (scleroderma) and in various organs, particularly in the lungs. [94] [95] [96] Endothelial damage and perivascular cellular infiltrates, with numerous T lymphocytes and monocytes, have been observed at an early stage of the pathologic conditions, 97, 98 before microscopic evidence of fibrosis. Myofibroblasts are the dominant source of ECM molecules during the fibroproliferative process. 99 Increased expression of MCP-1, TGF-b 1 and ET-1 has been demonstrated in the skin and in the lungs of affected individuals.
95,100-103 Notably, unlike classical monocytes and macrophages, 42 alveolar monocytes/macrophages of patients with systemic sclerosis and associated interstitial pulmonary fibrosis spontaneously release high amounts of fibronectin, 104 and lesional fibroblasts in the skin of individuals with systemic sclerosis aberrantly express one of the markers of the CD14 þ CD16 À subset of mononuclear cells from which fibrocytes likely originate, 38, 39 the MCP-1 receptor CCR2. 105 Furthermore, numerous cells synthesizing new collagen and expressing factor XIIIa, a marker of cells of the monocyte lineage, 106 have been detected in the lesional skin of individuals with scleroderma. 107 Differing from the spindleshaped cells present in low number in the clinically uninvolved skin, these fibroblasts do not appear to express CD34. 107 Taken together, these observations suggest that an increased, MCP-1-mediated, recruitment of precursors of the monocyte lineage may occur in the skin and in the lungs of patients with systemic sclerosis, possibly as a consequence of an initial endothelial damage 38, 39, 108 or the ischemic insults resulting from multiple microvascular obstructions. 108 The maturation of fibrocytes from these precursors at the tissue sites may be favored by the increased levels of TGF-b 1 and ET-1 in the micro-environment and the differentiation of fibrocytes into mature collagen-producing cells may be associated with a downregulation of CD34 expression, as it happens in cultured fibrocytes 6, 11, 17, 19, 21 or in labeled fibrocytes that have migrated to the sites of ongoing tissue fibrogenesis. 11 Interestingly, patients suffering from systemic sclerosis have low serum and tissue levels of SAP in comparison with healthy individuals, 5 and this alteration may contribute to an uncontrolled differentiation of fibrocytes in the skin and in organs involved by the disease.
Atherosclerosis
Atherosclerosis is an inflammatory disease that mostly involves the regions of large-and medium-sized arteries exposed to mechanical stress. 109, 110 Initial lesions are characterized by endothelial damage and accumulation of lipoproteins in the subendothelial space. 109, 111 Monocytes are then recruited into the subendothelial area, where they engulf modified lipids and become foam cells. 111 These cells, T lymphocytes and a few myofibroblasts form a fatty streak. 111 The subsequent accumulation of extracellular lipids leads to the formation of the fatty core of the atheroma in the intima. 112, 113 The intimal area overlaying the core contains foam cells and isolated myofibroblasts synthesizing new collagen. 113, 114 Further progression of the atherosclerotic lesions is characterized by the development of a fibrous cap (known as fibro-atheroma), with increased numbers of myofibroblasts and excessive deposition of collagen and other ECM molecules. 113, 114 The remodeling process may be either expansive or constrictive in nature, and in both cases, causes luminal narrowing with consequent tissue ischemia. 115 It is considered to represent the intimal response to continual injury, with failure to resolve the chronic inflammatory infiltrate, like the remodeling process that occurs in chronic wounds [116] [117] [118] and in the bronchial mucosa of asthmatic patients. 19 Fibrocytes coexpressing pro-collagen I and CD34 have been recently identified in the fibrous cap of human atherosclerotic lesions. 117, 118 Moreover, subendothelial myofibroblasts expressing the monocyte marker CD68 119 or CD34 118 have been found in lipid-rich areas of the atherosclerotic intima in human aorta 119 and in the fibrous cap of human carotid arteries, 118 suggesting that these cells originate from fibrocytes. Notably, one of the subsets of monocytes that are preferentially recruited into the arterial wall during experimentally induced atherosclerosis in mice 120 represents the murine counterpart of the human inflammatory subset of CD14 þ CD16 À mononuclear cells, expressing the MCP-1 receptor CCR2. 38, 39 Thus, the CD14 þ CD16 À CCR2 þ subpopulation may be involved in human atherogenesis and may contain fibrocyte precursors that contribute to the development of advanced atherosclerotic lesions. This hypothesis would be supported by data from epidemiologic studies 121, 122 that have suggested a major role of MCP-1 in the pathogenesis of atherosclerosis and disease progression.
It is noteworthy that the clinical significance of an atherosclerotic lesion is largely dependent on its composition, 123 which is critically determined by the balance between inflammation and fibrosis 124 and affects the stability of the plaque. Plaques with a thick fibrous cap and a small fatty core are reasonably stable, whereas plaques having a large fat core and thin fibrous cap are unstable 123 and can easily rupture, exposing or releasing the highly thrombogenic content of the core. 118 Thus, the accumulation of fibrocytes in the fibrous cap of the atherosclerotic lesion may have a beneficial effect in stabilizing the plaque that outweighs the detrimental increase in plaque volume. 118 Because fibrocytes seem to derive from the immature population of bone marrow-derived precursors of the monocyte lineage 5,9,10 from which foam cells also originate, 120 the preferential differentiation of these precursors into fibrocytes rather than inflammatory monocytes and foam cells might at the same time stabilize the plaque through the formation of the fibrous cap and limit the expansion of the fatty core, as recently proposed. 118 Athero-sclerotic lesions are known to contain high levels of TGF-b 1 123 and ET-1, 108 and both these pro-fibrotic factors may play a key role in promoting the differentiation of fibrocytes into myofibroblasts, thereby favoring the development of the fibrous cap.
Reactive Fibrosis in Chronic Pancreatitis and Cystitis
Stromal cells expressing CD34 have been found in tissue specimens from patients with chronic pancreatitis 13, 29 and chronic cystitis. 24 In chronic pancreatitis, the accumulation of CD34 þ fibrocyte-like cells appears to be associated with a parallel increase in the number of a-SMA myofibroblasts and these alterations are not observed in the normal pancreatic stroma. 13 The phenotype of the CD34-positive stromal cells and their relative contribution to the population of lesional myofibroblasts in these pathologic conditions remain to be elucidated.
Tumor-Induced Stromal Reaction
Immature monocytes released from the bone marrow are actively recruited into solid tumors from the local circulation and represent a prominent component of the leukocyte infiltrate, particularly in malignant lesions. 108 In mice, the mesenchymal cells that contribute to the development of tumor stroma also appear to originate, at least in part, from bone marrow-derived precursors. 50, 125, 126 Several studies have demonstrated the presence of CD34-positive, fibrocytelike stromal cells in various human benign and invasive tumors. 13, [24] [25] [26] [27] [28] [29] [30] [31] [32] In general, analysis of cells single stained for CD34 or a-SMA on serial tissue sections has indicated that CD34 þ a-SMA À fibroblasts are usually found in the stroma encapsulating benign tumors, whereas CD34 À a-SMA þ stromal cells are particularly frequent around invasive carcinoma. Because fibrocytes exhibit antigen-presenting activity 34 and activate cytotoxic T lymphocytes, 35 the apparent selective loss of the stromal network of CD34 þ fibrocyte-like Figure 1 Signals that may promote (dashed green arrows) 3, 12, 23, 48 or inhibit (dashed red arrows) 5,9,10,48 the accumulation of fibrocytes during human reparative or reactive fibroses. The possible cell sources of cytokines, growth factors and chemokines (gray arrows) derive from published studies 16, 63, 64 or reviews. 19, 38, 39, 49, 62, 65, 66, 72, 108, 118, 128 The maturation of fibrocytes from their bone marrow-derived precursors (solid black arrows) may predominantly occur at tissue sites rather than in the circulation, because SAP is a constitutive serum protein that may inhibit the maturation process. 5,9,10,48 MCP-1, CXCL12 and the ligands of CCR7, CCL19 and CCL21 may all contribute to various extents to the recruitment of fibrocyte precursors into tissue sites (dashed black arrows), depending on the pathological condition and the nature of the inflammatory infiltrate. However, in disorders associated with low serum levels of SAP, such as systemic sclerosis, 5 or with high circulating levels of TGF-b 1 , such as extensive burn injuries, 4 there may be appreciable numbers of fibrocytes in the peripheral blood and these cells may be directly recruited into lesional areas through CXCR4-or CCR7-mediated pathways (dashed black arrows reviews. 19, 49, 65, 66, 72, 108, 118 Fibrocytes themselves release growth factors, such as connective tissue growth factor (CTGF) and TGF-b 1 , 2,36 which may induce the proliferation of resident fibroblasts and promote their differentiation into myofibroblasts in concert with the ET-1 and TGF-b 1 produced by other cell types (solid green arrows). The differentiation of fibrocytes into mature myofibroblasts is associated with the loss of surface markers that are currently used to distinguish fibrocytes and fibrocyte-derived cell from the myofibroblasts originating as a result of the activation of resident fibroblasts. Moreover, fibrocytes can be easily developed from circulating CD14 þ mononuclear cells and expanded ex vivo. Given the propensity of intravenously injected fibrocytes to migrate into inflamed tissues, 3, 11 expanded autologous cells could be used to deliver therapeutic gene constructs to improve ineffective repair processes and to encapsulate cancerous cells or cause their death.
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